Independent perspective. Actionable security.Know what matters · Reduce exposure

Vulnerability Assurance / Intelligence

Apple Use-After-Free Vulnerability CVE-2023-43000

Historical catalog analysis: CISA added this entry on March 05, 2026. The entry reflects catalog information retrieved on August 31, 2026, not a snapshot archived on the inclusion date. Check current vendor guidance before acting.

What the vulnerability is

CVE-2023-43000 is a use-after-free (CWE-416) vulnerability identified in several Apple products. The flaw occurs during the processing of maliciously crafted web content, which could lead to memory corruption on the affected system.

Exposure and applicability

This vulnerability affects a broad range of Apple endpoints and browsing environments, specifically:
* Operating Systems: macOS, iOS, and iPadOS.
* Web Browser: Safari 16.6.

Exposure occurs when an affected device processes specific web content designed to trigger the memory corruption. Organizations with large fleets of mobile devices or macOS workstations utilizing Safari are most susceptible to this entry path.

Remediation priorities

Based on our analysis, vulnerability management teams should prioritize remediation based on the following hierarchy:
1. Vendor Patching: The primary corrective action is to apply mitigations as specified in Apple’s vendor instructions. This is the most direct method to address the underlying memory corruption flaw.
2. Version Control: Identify and update all instances of Safari 16.6 across the environment, as this specific version is explicitly listed as affected.
3. Product Decommissioning: In scenarios where mitigations are unavailable or cannot be applied to legacy hardware, our analysis suggests discontinuing use of the product to eliminate the exposure path.

How to validate remediation

To ensure that exposure has been reduced, defenders should move beyond simple version checks. While confirming a version update is a necessary first step, it does not alone prove that the vulnerability is mitigated in a live environment.

Validation should include:
* Configuration Audit: Verifying through centralized device management (MDM) that the specific vendor-recommended security updates have been successfully installed and initialized on all endpoints.
* Deployment Verification: Comparing current build numbers against the vendor’s patched release list to ensure no devices remain on Safari 16.6 or vulnerable OS builds.

Limits and open questions

There are several unknowns regarding this vulnerability that impact risk assessment:
* Exploitation Status: While included in the CISA Known Exploited Vulnerabilities catalog, the source lists known ransomware campaign use as “Unknown.”
* Residual Risk: Even after patching, residual risk may exist if users maintain outdated browser extensions or if other unpatched memory corruption flaws exist in the same processing chain.
* Mitigation Efficacy: The effectiveness of any compensating controls (such as web filtering) is limited because the vulnerability is triggered by the content itself once it reaches the browser.

Source and editorial note

CVE-2023-43000: Apple Multiple products Use-After-Free Vulnerability · Source date: March 05, 2026 · Retrieved August 31, 2026.

Material facts are tied to the cited primary source. Recommendations are independent defensive analysis unless attributed to the source. Confirm consequential decisions against current authoritative guidance.

Archive date: March 08, 2026. The displayed post date is assigned three days after the source date to organize this retrospective archive; it does not mean this site published the analysis then. First published by this site: September 19, 2026 at 00:09 UTC.

Request a Vulnerability Assessment

Turn security intelligence into action.

Discuss your exposure, priorities, and the evidence needed to validate the outcome.

Request a security assessment ↗

Turn security intelligence into action.

Understand exposure, prioritize the response, and define evidence for the outcome.

Request a Security Assessment